Studies that used common variants in PNPLA3, TM6SF2 and GCKR as instruments to investigate the relationship between NAFLD and coronary artery disease (CAD) have reported contrasting results. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.